STATE OF WEST VIRGINIA
DEPARTMENT OF HUMAN SERVICES
BUREAU FOR MEDICAL SERVICES

Alex J.Mayer
Cabinet Secretary

Cynthia Beane, MSW, LCSW
Commissioner

Office of Pharmacy Services
Prior Authorization Criteria
Zurzuvae™
(zuranolone)
Effective 2/26/2025
Prior Authorization Request Form

ZURZUVAE (zuranolone) is a neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator indicated for the treatment of postpartum depression (PPD) in adults.

CRITERIA FOR APPROVAL:

1. The patient is within the age range as recommended by the Food and Drug Administration (FDA) label; **AND**
2. The patient has a diagnosis of post-partum depression (PPD); **AND**
3. Zurzuvae is being prescribed by, or in consultation with a M.D./D.O. psychiatrist or obstetrician-gynecologist; **AND**
4. The patient is ≤ 6 months postpartum and the patient has had a major depressive episode with onset of symptoms associated with post-partum depression that began during the third trimester of pregnancy or up to 4 weeks post-delivery; **AND**
5. The patient has been diagnosed with severe post-partum depression and severity has been assessed using a validated depression tool (such as the Zung Depression scale, Patient Health Questionnaire (PHQ9), Edinburgh Postnatal Depression scale (EPDS), or the Hamilton Rating Scale for Depression) clearly indicating severe depression; **AND**
6. The patient has tried and had an inadequate response to at least one antidepressant for their current depressive episode at a maximally tolerated therapeutic dose for a minimum duration of 4 weeks; **AND**
7. The patient has not received prior treatment with Zurzuvae or Zulresso for the current pregnancy; **AND**
8. The patient is not currently pregnant and is using effective contraception during treatment with Zurzuvae and for one week after the final dose; **AND**
9. The patient has been screened for bipolar disorder and the diagnosis has been ruled out (attach screening tool such as mood disorder questionnaire) AND the patient does not have a medical history of schizophrenia, and/or schizoaffective disorder.

NOTE: The patient should not drive a motor vehicle or engage in other potentially hazardous activities requiring complete mental alertness, such as operating machinery, until at least 12 hours after taking each dose of Zurzuvae for the duration of the 14-day treatment course.

Zurzuvae treatment has not been evaluated for > 1 course of treatment per pregnancy. Cannot be renewed for current PPD episode.